100K Pathogen Genome Project Selects PacBio SMRT(R) DNA Sequencing to Generate High-Quality, Finished Genomes

100K Pathogen Genome Project Selects PacBio SMRT(R) DNA Sequencing to Generate
High-Quality, Finished Genomes

PacBio Long Sequence Reads Provide Ability to Close Genomes; SMRT Kinetic
Information Enables Epigenetic Characterization

MENLO PARK, Calif., Jan. 8, 2013 (GLOBE NEWSWIRE) -- Pacific Biosciences of
California, Inc. (Nasdaq:PACB) provider of the PacBio^® RS High Resolution
Genetic Analyzer, and the University of California, Davis (UC Davis) today
announced a partnership for the 100K Pathogen Genome Project. As part of the
project, Pacific Biosciences' Single Molecule, Real-Time (SMRT^®) technology
will be used to sequence the genomes from at least 1,000 foodborne pathogen
samples to completion, and to elucidate their epigenomes. These bacteria
represent major illness-causing pathogens, including Salmonella,
Campylobacter, E. coli, Vibrio, and Listeria.

The 100K Genome Project was founded by the U.S. Food & Drug Administration,
Agilent Technologies, and the laboratory of Dr. Bart Weimer at UC Davis to
create a consortium of partners from around the world that will sequence
100,000 foodborne pathogens using next-generation sequencing. This initiative
addresses a significant shortage of bacterial pathogen information for use in
designing molecular diagnostics, creates a resource to expand our
understanding of infection mechanisms, and constructs a public repository for
new insights into bacterial evolution by using large-scale genomics.

Pacific Biosciences' SMRT sequencing technology generates sequence reads an
order of magnitude longer than other leading DNA sequencing technologies,
thereby facilitating efficient de novo microbial genome assemblies. Long reads
are critical for resolving genetic complexity in the assembly and finishing of
genomes. The use of SMRT sequencing for the automated finishing of microbial
genomes has been demonstrated in multiple recent publications, including for
the genetic analysis of the Haitian cholera and German E. coli outbreaks.

The kinetic information acquired during SMRT sequencing can be used to
elucidate the epigenome of bacteria. Epigenetic DNA base modifications, such
as methylation, play an important role in the phenotypic variation,
adaptability and pathogenicity of many bacteria, but they have been difficult
to study due to the lack of a sequencing method to detect them. As part of the
100K Genome Project, the epigenomes of the pathogenic strains subjected to
SMRT sequencing will be characterized, adding an important dataset to public
database repositories.

"SMRT sequencing has been shown to be a powerful technology for the
comprehensive determination of microbial genomes and epigenomes," said Dr.
Jonas Korlach, Chief Scientific Officer of Pacific Biosciences. "Through the
combination of long reads, high consensus accuracy, and the lack of sequencing
bias to GC content or sequence contexts, SMRT sequencing harbors the necessary
requirements to construct finished genomes in an unbiased, hypothesis-free
manner. The ability to detect methylation as part of the sequencing process is
unique to SMRT sequencing, and will provide an invaluable resource to
illuminate the epigenetic components controlling bacterial pathogenicity."

"We are very pleased to utilize SMRT sequencing as part of the 100K Genome
Project," said Bart Weimer, Professor and Director of the 100K Genome Project,
"SMRT technology will enable production of complete genomes that will
contribute great value toward databases for biological insight, new biomarker
discovery, and reference genomes for food pathogen detection. A project of
this scale is needed since microbial genome variations, including structural
variations, the acquisition and loss of mobile elements, and phages or
plasmids, are very difficult or impossible to detect without a de novo
sequencing and genome assembly approach, yet they have a significant impact on
food safety."

The partnership will entail the sequencing of at least 1,000 samples by the
100K consortium member labs with access to the PacBio RS instrumentation,
including pipeline constructions for high-throughput pathogen sequencing, de
novo genome assemblies, epigenome determination, and data curation and
deposition. Pacific Biosciences will provide technical guidance and training
to support these activities, and interface closely with the involved
laboratories to assist in the efficient construction of these pipelines.

For more information, please visit
http://100kgenome.vetmed.ucdavis.edu/index.cfm and www.pacb.com.

About Pacific Biosciences

Pacific Biosciences of California, Inc. (Nasdaq:PACB) offers the PacBio^® RS
High Resolution Genetic Analyzer to help scientists solve genetically complex
problems. Based on its novel Single Molecule, Real-Time (SMRT^®) technology,
the company's products enable: targeted sequencing to more comprehensively
characterize genetic variations; de novo genome assembly to more fully
identify, annotate and decipher genomic structures; and DNA base modification
identification to help characterize epigenetic regulation and DNA damage. By
providing access to information that was previously inaccessible, Pacific
Biosciences enables scientists to increase their understanding of biological
systems.

About The 100K Genome Project

Established in March 2012 by UC Davis, Agilent Technologies and the U.S. Food
and Drug Administration, the 100K Genome Project is a landmark consortium that
addresses the persistent food safety concerns by engaging world-wide partners
to create a publicly available genetic database of the most common foodborne
disease-causing microbes. By sequencing 100,000 pathogen genomes, the project
will bring a new paradigm to public health to empower precise and robust
molecular testing in the food chain – from the farm to the kitchen table. For
more information, visit http://100kgenome.vetmed.ucdavis.edu.

About UC Davis

For more than 100 years, UC Davis has engaged in teaching, research and public
service that matter to California and transform the world. Located close to
the state capital, UC Davis has more than 33,000 students, more than 2,500
faculty and more than 21,000 staff, an annual research budget of nearly $750
million, a comprehensive health system and 13 specialized research centers.
The university offers interdisciplinary graduate study and more than 100
undergraduate majors in four colleges — Agricultural and Environmental
Sciences, Biological Sciences, Engineering, and Letters and Science. It also
houses six professional schools — Education, Law, Management, Medicine,
Veterinary Medicine and the Betty Irene Moore School of Nursing.

CONTACT: For Pacific Biosciences:
        
         Media:
         Maurissa Messier
         For Pacific Biosciences
         760.539.7417
         maurissa@bioscribe.com
        
         Investors:
         Trevin Rard
         Pacific Biosciences
         650.521.8450
         ir@pacificbiosciences.com
        
         For UC Davis:
         Media:
         Patricia Bailey
         Science/Agriculture writer
         UC Davis News Service
         (530) 752-9843 office
         (530) 219-9640 cell
         pjbailey@ucdavis.edu
        
         Scientific:
         Dr. Bart Weimer
         Professor, School of Veterinary Medicine
         Director, 100K Genome Project
         Director, BGI@UCDavis
         (530) 754-0109
         bcweimer@ucdavis.edu